Preclinical analysis shows calcium silicate cement enhances immunogenic cell death in osteosarcoma, indicating potential for bone cancer treatment.
This composite cement constitutes a dual-functional system capable of supporting bone defect repair while providing a photothermal antitumor effect, with potential immunogenic properties. The combination of improved material properties and efficient PTT performance highlights its promise as a strategy for treating bone tumors in a preclinical setting. These results support further development of this material for future translational studies in bone tissue engineering and oncology.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: